| |
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now. 
|
|
Today’s Big NewsJan 3, 2024 |
| By Nick Paul Taylor Boehringer Ingelheim is having another crack at using RNA to treat metabolic-associated steatohepatitis (MASH). Six years after inking deals for a pair of prospects, the German drugmaker has committed more than $2 billion in biobucks to enter into a multi-target pact with a Chinese biotech and its Swedish subsidiary. |
|
|
|
By Angus Liu Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients. |
By Conor Hale The new model is made to be significantly smaller, thinner and lighter compared to the company’s previous Zio XT ECG-recording patch. |
By James Waldron Goldman Sachs is planning to make a splash in the life sciences sector, closing a $650 million for its first fund aimed at the drug development space. |
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join industry experts to hear how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now. 
|
|
By Kevin Dunleavy Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market with their dominance. Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales. |
By Andrea Park A new set of early study results have suggested that in addition to offering a longer-term alternative to standard CGMs, GlucoTrack’s technology also shows promise in improving on its competitors’ accuracy. |
By Fraiser Kansteiner GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme. |
By Annalee Armstrong Roche is ready for the remix—Therapeutics that is. The Swiss pharma has signed a $30 million upfront deal that could rise to $1 billion down the line to develop new small molecules. |
By Zoey Becker The agreement amends terms of the companies' 2019 partnership on heart med Nexletol and dismisses Esperion's lawsuit over milestone payments ahead of a potential European label expansion. |
By James Waldron Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public. |
By Andrea Park After beginning the U.S. launch of its AspyreRx digital therapeutic for Type 2 diabetes last fall, Better Therapeutics is kicking off the new year by ramping up that rollout. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
This resource describes some key factors worth considering as you think through how to construct an effective and robust screening cascade. We will focus initially on the hit-to-lead phase, as this encompasses the types of assays required and highlights some general considerations. Download now. 
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
Whitepaper Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
Whitepaper High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| |
|
